Previous 10 | Next 10 |
Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 (olanzapine) and AJOVY ® (fremanezumab) injection Presentation highlights include data for AUSTEDO in the tardive dyskinesia (TD) START study on real-...
2023-08-30 17:36:00 ET Summary Catalyst Pharmaceuticals reported a significant increase in product revenues, with a YoY growth of 87.5% in Q2 2023. The company maintains a strong financial position with $178.8M in cash and cash equivalents and no immediate need for additional fina...
2023-08-30 10:38:05 ET More on Alkermes Alkermes: A Complicated Story Right Now Lybalvi: Weighing In Light, But Tipping Alkermes' Scales Alkermes plc 2023 Q2 - Results - Earnings Call Presentation Alkermes plc ( ALKS ) Q2 2023 Earnings Call Transcript ...
2023-08-24 14:12:04 ET More on generic drugmakers Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market Viatris: Turning Point For Cheap Pharma Stock Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain Novartis schedules Sandoz...
2023-08-24 02:48:55 ET Summary Abrams' 13F portfolio value increased from $3.16B to $3.48B this quarter. The number of holdings in the portfolio increased from 15 to 16. The top three stakes in the portfolio make up approximately 45% of the total. This article is par...
2023-08-22 13:34:38 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited ( TEVA ) Q2 2023 Earnings Call Transcript Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain Teva Pharmaceutical Industries Limited 2023 Q2 - Results -...
2023-08-21 16:51:39 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited ( TEVA ) Q2 2023 Earnings Call Transcript Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain Teva Pharmaceutical Industries Limited 2023 Q2 - Results -...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached a deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ) to settle the criminal price-fixing charges brought against Teva in 2020. Under the DPA, which will...
2023-08-18 13:09:45 ET Summary On August 7, Viatris released its financial results for the 2nd quarter of 2023, which, after a long time, finally managed to beat analysts' expectations. Viatris' revenue for the second quarter of 2023 was $3.92 billion, up 5.1% from the previous qu...
2023-08-14 16:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...